Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix1131
Abstract: Clinical Trials Registration NCT02263326. read more here.
Keywords: human immunodeficiency; maintains human; plus lamivudine; immunodeficiency virus ... See more keywords